Abstract: FR-PO992
Investigating Hepatocyte Nuclear Factor 4 Alpha as a Central Regulator of Kidney Graft Repair
Session Information
- Transplantation: Basic
October 25, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 2101 Transplantation: Basic
Authors
- Neupane, Slaghaniya, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
- Petrovic, Stefan, University Health Network, Toronto, Ontario, Canada
- Saha, Aninda Dibya, Stanford Medicine, Stanford, California, United States
- Allen, Maya A., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
- Sachewsky, Nadia, University Health Network, Toronto, Ontario, Canada
- John, Rohan, University Health Network, Toronto, Ontario, Canada
- Selzner, Markus, University Health Network, Toronto, Ontario, Canada
- Robinson, Lisa, Sick Kids Foundation, Toronto, Ontario, Canada
- Clotet Freixas, Sergi, McMaster University, Hamilton, Ontario, Canada
- Konvalinka, Ana, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
Background
Kidney transplantation is the optimal treatment for end-stage kidney disease. However, ischemia-reperfusion injury (IRI) harms all transplanted kidneys, limiting their short- and long-term survival. Previously, we determined that superior kidney function/structure after IRI is associated with preserved expression of mitochondrial proteins during normothermic ex vivo kidney perfusion (NEVKP). We identified a potential transcriptional regulator of these mitochondrial proteins, hepatocyte nuclear factor 4a (HNF4A), which may present a novel target for kidney repair. Our goal is to determine whether a novel HNF4A agonist, N-trans caffeoyltyramine (NCT), protects kidneys from IRI. We will evaluate the effectiveness of NCT treatment in vitro studying male and female primary proximal tubular cells (PTECs), and in vivo studying male and female mice.
Methods
First, we inhibited HNF4A in primary male and female PTECs, using a pharmacologic or genetic approach. We then assessed gene expression, cell death and mitochondrial function. Next, we treated PTECs with NCT/vehicle and examined cell death and expression of HNF4A target genes. Lastly, male and female mice were subjected to bilateral IRI, and kidney function and structure were assessed on post-operative day 2 and 14.
Results
HNF4A inhibition in vitro increased PTEC death and decreased mitochondrial function, while NCT increased the expression of HNF4A and mitochondrial genes, suggesting that NCT may be protective. We developed a sex-specific model of bilateral IRI and demonstrated that warm ischemia (27-minutes in males, 40-minutes in females) impairs kidney function on post-operative day 2, indicated by elevated serum creatinine and tubular injury. Mice also developed tubulointerstitial fibrosis on post-operative day 14.
Conclusion
Based on the preliminary results, HNF4A is important for the metabolic function and viability of PTECs. We will next administer NCT to mice prior to IRI and examine whether HNF4A agonist preserves mitochondria and improves kidney function and structure.